Document is current
Any future updates will be listed below
-
Authors
Gonzalez Trotter, Dinko
Donahue, Stephen
Wynne, Chris
Ali, Shazia
Parasoglou, Prodromos
Boyapati, Anita
Mohammadi, Kusha https://orcid.org/0000-0002-7844-7537
Musser, Bret J.
Meier, Pretty
Mastaitis, Jason https://orcid.org/0000-0002-9991-3509
Sleeman, Mark W.
Glass, David J. https://orcid.org/0000-0001-6187-4164
Gasparino, Evelyn
Trejos, Jesus https://orcid.org/0000-0003-4816-8139
Davis, John D.
Hirshberg, Boaz
Pordy, Robert https://orcid.org/0000-0002-8001-6795
Yancopoulos, George D.
Herman, Gary A. https://orcid.org/0000-0003-4433-6529
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals (N/A)
- License Information
-
More Information
Article History
Received: 4 April 2024
Accepted: 9 April 2025
First Online: 13 May 2025
Competing interests
: D.G.T., S.A., P.P., A.B., K.M., B.J.M., P.M., D.J.G., E.G., J.T., J.D.D., B.H., R.P., G.D.Y., and G.A.H. are employees and stockholders of Regeneron Pharmaceuticals, Inc. J.M. and M.W.S. are employees and stockholders of Regeneron Pharmaceuticals, Inc. who report having a patent pending, which has been licensed and receiving royalties with Regeneron Pharmaceuticals, Inc. S.D. was an employee of and holds stocks in Regeneron Pharmaceuticals, Inc. C.W. is an employee of and shareholder in New Zealand Clinical Research. The authors declare no other competing interests.
